|
|
| França,P.H.C.; Coelho,H.S.M.; Brandão,C.E.; Segadas,J.A.; Quintaes,R.F.; Carrilho,F.J.; Ono-Nita,S.; Mattos,A.A.; Tovo,C.; Gouvea,V.S.; Sablon,E.; Vanderborght,B.O.M.. |
| Given the loss of therapeutic efficacy associated with the development of resistance to lamivudine (LMV) and the availability of new alternative treatments for chronic hepatitis B patients, early detection of viral genotypic resistance could allow the clinician to consider therapy modification before viral breakthrough and biochemical relapse occur. To this end, 28 LMV-treated patients (44 ± 12 years; 24 men), on their first therapy schedule, were monitored monthly at four Brazilian centers for the emergence of drug resistance using the reverse hybridization-based INNO-LiPA HBV DR assay and occasionally sequencing (two cases). Positive viral responses (HBV DNA clearance) after 6, 12, and 18 months of therapy were achieved by 57, 68, and 53% of patients,... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hepatitis B; Antiviral therapy; Lamivudine; Drug resistance; YMDD variants; Hepatitis B virus. |
| Ano: 2007 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007001200003 |
| |
